[1] World Health Organization. WHO Cancer Today. http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed Nov 7th, 2019.
[2] Murray L, Henry A, Hoskin P, Siebert F-A, Venselaar Jack. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol. 2014;110(2):213-28.
[3] Wallis CJ, Mahar AL, Choo R, Herchorn S, Kodama RT, Shah PS et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851.
[4] Barbosa PV, Thomas IC, Srinivas S, Buyyounouski MK, Chung BI, Chertow GM et al. Overall survival in patients with localized prostate cancer in the US veterans health administration: Is PIVOT generalizable? Eur Urol. 2016;70(2):227-30.
[5] Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69-77.
[6] Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S et al. EAU Guidelines: Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/. Accessed Nov 7th 2019.
[7] International Commission on Radiological Protection. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP publication 98. Ann ICRP. 2005;35(3):3-50.
[8] Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(1):58-68.
[9] Vuolukka K, Auvinen P, Palmgren JE, Voutilainen T, Aaltomaa S, Kataja V. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer. Brachytherapy. 2019;18(5)583-588.
[10] Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57(3):315-21.
[11] Musunuru H, Mason M, Murray L, Al-Qaisieh B, Bownes P, Smith J et al. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer. Clin Oncol (R Coll Radiol). 2014;26(4):210-5.
[12] Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol. 2011;29(34):4510-5.
[13] Fernandez Ots A, Browne L, Chin YS, Malouf D, Wong K, Bucci J. The risk of second malignancies after 125I prostate brachytherapy as monotherapy in a single Australian institution. Brachytherapy. 2016;15(6):752-759.
[14] Cosset JM, Belin L, Wakil G, Flam T, Thiounn N, Pierrat N et al. Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. Cancer Radiother. 2017;21(3):210-215.
[15] Hamilton SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T et al. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy. Int J Radiat Oncol Biol Phys. 2014;90(4):934-941.
[16] Van Hemelrijck M, Feller A, Garmo H, Valeri F, Korol D, Dehler S et al. Incidence of second malignancies for prostate cancer. PLoS One. 2014;9(7):e102596.
[17] Jin T, Song T, Deng S, Wang K. Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. Urol Int. 2014;93(3):279-88.
[18] The NORDCAN project – Cancer statistics from the Nordic countries. http://www-dep.iarc.fr/NORDCAN/english/frame.asp. Accessed Nov 8th 2019.